Tapewire

NYSE · USD

BDX

BECTON DICKINSON & CO

Export transactions ↓
Tapewire entity
2498
SEC CIK
0000010795
Parsed reports
649

Last 12 months

Inside the activity.

0 purchase rows · 20 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202501
Dec 202503
Jan 202603
Feb 202602
Mar 202601
Apr 202601
May 202601
Jun 202604
Jul 202601
Aug 202603
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 02, 2026 Filed Sep 3, 2026 23:24 UTC
Roque VitorEVP & Chief Financial Officer
Tax withholdingCommon Stock 190 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-060580 · wk-form4_1788477895.xml · nonDerivative · entry 1

Roque Vitor · CIK 0002098881 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,041

F1 · shares: Represents shares withheld for payment of withholding taxes in connection with vesting of previously reported restricted stock unit awards

Read SEC document
August 26, 2026 Filed Aug 27, 2026 20:28 UTC
Feld MichaelEVP, Chief Revenue Officer
SaleCommon Stock 165 $188.49 $31,100.85
Disclosure

SEC source: 0001628280-26-059269 · wk-form4_1787862519.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,720

Read SEC document
August 20, 2026 Filed Aug 24, 2026 20:19 UTC
Feld MichaelEVP, Chief Revenue Officer
Tax withholdingCommon Stock 1,049 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-058647 · wk-form4_1787602744.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, Chief Revenue Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,885

F1 · shares: Represents shares withheld for payment of withholding taxes in connection with vesting of previously reported restricted stock unit awards

Read SEC document
August 13, 2026 Filed Aug 14, 2026 20:36 UTC
Polen Thomas E JrDirector · Chairman, CEO and President
Exercise / conversionStock Appreciation Rights · Derivative 43,278 $0.00 Strike: $167.25 $0.00
Disclosure

SEC source: 0001628280-26-057166 · wk-form4_1786739778.xml · derivative · entry 4

Polen Thomas E Jr · CIK 0001621793 · Director · Chairman, CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 43,278 shares

Expires 2027-11-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Award terms reflect the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

F2 · derivative.exercise_date: The stock appreciation rights vested in four annual installments beginning November 26, 2018.

Read SEC document
August 13, 2026 Filed Aug 14, 2026 20:36 UTC
Polen Thomas E JrDirector · Chairman, CEO and President
SaleCommon Stock 4,152 $185.00 $768,120.00
Disclosure

SEC source: 0001628280-26-057166 · wk-form4_1786739778.xml · nonDerivative · entry 3

Polen Thomas E Jr · CIK 0001621793 · Director · Chairman, CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,163

Read SEC document
August 13, 2026 Filed Aug 14, 2026 20:36 UTC
Polen Thomas E JrDirector · Chairman, CEO and President
Disposition to issuerCommon Stock 39,126 $185.00 $7,238,310.00
Disclosure

SEC source: 0001628280-26-057166 · wk-form4_1786739778.xml · nonDerivative · entry 2

Polen Thomas E Jr · CIK 0001621793 · Director · Chairman, CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,315

Read SEC document
August 13, 2026 Filed Aug 14, 2026 20:36 UTC
Polen Thomas E JrDirector · Chairman, CEO and President
Exercise / conversionCommon Stock 43,278 $167.25 $7,238,245.50
Disclosure

SEC source: 0001628280-26-057166 · wk-form4_1786739778.xml · nonDerivative · entry 1

Polen Thomas E Jr · CIK 0001621793 · Director · Chairman, CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,441

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 11, 2026 Filed Aug 12, 2026 21:27 UTC
Goette RolandEVP and President, EMEA
SaleCommon Stock 2,438 $180.84 $440,887.92
Disclosure

SEC source: 0001628280-26-056366 · wk-form4_1786570038.xml · nonDerivative · entry 1

Goette Roland · CIK 0001708067 · EVP and President, EMEA

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,856

F1 · shares: Securities sold were common stock acquired through the Becton, Dickinson and Company Global Share Investment Program (the "GSIP").

F2 · balance_after: Holdings reflect the addition of dividends the reporting person received as part of the equity adjustment made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

Read SEC document
August 06, 2026 Filed Aug 6, 2026 20:47 UTC GrantRights to Common Stock Under BD Deferred Compensation Plan · Derivative 189 $165.62 $31,302.18
Disclosure

SEC source: 0001628280-26-054422 · wk-form4_1786049274.xml · derivative · entry 1

Huffines Robert Luther · CIK 0001728221 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 595

Underlying: Common Stock · 189 shares

Expires not disclosed

F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F3 · balance_after: Includes rights acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
August 06, 2026 Filed Aug 6, 2026 20:47 UTC GrantRights to Common Stock Under BD Deferred Compensation Plan · Derivative 94 $165.62 $15,568.28
Disclosure

SEC source: 0001628280-26-054418 · wk-form4_1786049218.xml · derivative · entry 1

Byington Carrie L · CIK 0001890265 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,810

Underlying: Common Stock · 94 shares

Expires not disclosed

F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F3 · balance_after: Includes rights acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
July 27, 2026 Filed Jul 28, 2026 15:16 UTC
Feld MichaelEVP, Chief Revenue Officer
SaleCommon Stock 75 $157.13 $11,784.75
Disclosure

SEC source: 0001628280-26-049989 · wk-form4_1785251777.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,934

Read SEC document
July 02, 2026 Filed Jul 6, 2026 19:16 UTC
Muhsin BilalEVP & President Connected Care
Tax withholdingCommon Stock 1,935 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-047193 · wk-form4_1783365371.xml · nonDerivative · entry 2

Muhsin Bilal · CIK 0001734507 · EVP & President Connected Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,359

F3 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units previously reported on Table I.

Read SEC document
July 01, 2026 Filed Jul 6, 2026 19:16 UTC
Muhsin BilalEVP & President Connected Care
GrantCommon Stock 14,342 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-047193 · wk-form4_1783365371.xml · nonDerivative · entry 1

Muhsin Bilal · CIK 0001734507 · EVP & President Connected Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,294

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Read SEC document
June 26, 2026 Filed Jun 27, 2026 00:47 UTC
Feld MichaelEVP, Chief Revenue Officer
SaleCommon Stock 75 $152.80 $11,460.00
Disclosure

SEC source: 0001628280-26-045864 · wk-form4_1782521257.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,009

Read SEC document
June 24, 2026 Filed Jun 25, 2026 14:16 UTC
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
SaleCommon Stock 1,100 $145.66 $160,226.00
Disclosure

SEC source: 0001628280-26-045374 · wk-form4_1782396959.xml · nonDerivative · entry 1

Garrison Michael David · CIK 0001944816 · EVP & Pres Med.Essntl&BioPharm

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,172

Read SEC document
June 10, 2026 Filed Jun 11, 2026 21:21 UTC
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
SaleCommon Stock 1,100 $151.48 $166,628.00
Disclosure

SEC source: 0001628280-26-042571 · wk-form4_1781212873.xml · nonDerivative · entry 1

Garrison Michael David · CIK 0001944816 · EVP & Pres Med.Essntl&BioPharm

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,272

F1 · balance_after: Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 18:11 UTC
Menziuso PeterEVP and President, BDI
GrantCommon Stock 14,258 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-039738 · wk-form4_1780423907.xml · nonDerivative · entry 1

Menziuso Peter · CIK 0002135899 · EVP and President, BDI

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,258

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 16:44 UTC
Polen Thomas E JrDirector · Chairman, CEO and President
Exercise / conversionStock Appreciation Rights · Derivative 20,209 $0.00 Strike: $126.16 $0.00
Disclosure

SEC source: 0001628280-26-040095 · wk-form4_1780505062.xml · derivative · entry 4

Polen Thomas E Jr · CIK 0001621793 · Director · Chairman, CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,209 shares

Expires 2026-11-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

F3 · shares: Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

F4 · derivative.exercise_date: The stock appreciation rights vested in four annual installments beginning November 26, 2017.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 16:44 UTC
Polen Thomas E JrDirector · Chairman, CEO and President
SaleCommon Stock 2,764 $146.35 $404,511.40
Disclosure

SEC source: 0001628280-26-040095 · wk-form4_1780505062.xml · nonDerivative · entry 3

Polen Thomas E Jr · CIK 0001621793 · Director · Chairman, CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,163

F1 · price: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request.

F2 · balance_after: Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 16:44 UTC
Polen Thomas E JrDirector · Chairman, CEO and President
Disposition to issuerCommon Stock 17,445 $146.15 $2,549,586.75
Disclosure

SEC source: 0001628280-26-040095 · wk-form4_1780505062.xml · nonDerivative · entry 2

Polen Thomas E Jr · CIK 0001621793 · Director · Chairman, CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,235

Read SEC document
June 01, 2026 Filed Jun 3, 2026 16:44 UTC
Polen Thomas E JrDirector · Chairman, CEO and President
Exercise / conversionCommon Stock 20,209 $126.16 $2,549,567.44
Disclosure

SEC source: 0001628280-26-040095 · wk-form4_1780505062.xml · nonDerivative · entry 1

Polen Thomas E Jr · CIK 0001621793 · Director · Chairman, CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,680

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 26, 2026 Filed May 27, 2026 17:41 UTC
Feld MichaelEVP, Chief Revenue Officer
SaleCommon Stock 75 $147.35 $11,051.25
Disclosure

SEC source: 0001628280-26-038382 · wk-form4_1779903672.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,084

Read SEC document
May 08, 2026 Filed May 8, 2026 21:26 UTC GrantRights to Common Stock Under BD Deferred Compensation Plan · Derivative 210 $149.04 $31,298.40
Disclosure

SEC source: 0001628280-26-033027 · wk-form4_1778275604.xml · derivative · entry 1

Huffines Robert Luther · CIK 0001728221 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404

Underlying: Common Stock · 210 shares

Expires not disclosed

F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F3 · balance_after: Includes rights acquired through dividend investment since the last report filed by the reporting person.

F4 · balance_after: Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person.

Read SEC document
May 08, 2026 Filed May 8, 2026 21:25 UTC GrantRights to Common Stock Under BD Deferred Compensation Plan · Derivative 105 $149.04 $15,649.20
Disclosure

SEC source: 0001628280-26-033022 · wk-form4_1778275502.xml · derivative · entry 1

Byington Carrie L · CIK 0001890265 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,699

Underlying: Common Stock · 105 shares

Expires not disclosed

F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F3 · balance_after: Includes rights acquired through dividend reinvestment since the last report filed by the reporting person.

F4 · balance_after: Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person.

Read SEC document
May 07, 2026 Filed May 8, 2026 21:04 UTC
Roque VitorEVP & Chief Financial Officer
GrantCommon Stock 1,721 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-032999 · wk-form4_1778274279.xml · nonDerivative · entry 1

Roque Vitor · CIK 0002098881 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,231

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

Read SEC document
April 27, 2026 Filed Apr 28, 2026 11:44 UTC
Feld MichaelEVP, Chief Revenue Officer
SaleCommon Stock 74 $151.94 $11,243.56
Disclosure

SEC source: 0001628280-26-027731 · wk-form4_1777376656.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,159

Read SEC document
April 06, 2026 Filed Apr 6, 2026 21:28 UTC
Neal Shana CarolEVP and Chief People Officer
Tax withholdingCommon Stock 1,146 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-023944 · wk-form4_1775510928.xml · nonDerivative · entry 1

Neal Shana Carol · CIK 0001735118 · EVP and Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,966

F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units previously reported on Table I.

F2 · balance_after: Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 17:49 UTC
Feld MichaelEVP, Chief Revenue Officer
SaleCommon Stock 75 $156.83 $11,762.25
Disclosure

SEC source: 0001628280-26-021644 · wk-form4_1774633795.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,233

F1 · balance_after: This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025.

Read SEC document
March 16, 2026 Filed Mar 17, 2026 18:46 UTC
Minnix LaneshaEVP and General Counsel
GrantCommon Stock 7,492 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-018607 · wk-form4_1773773181.xml · nonDerivative · entry 1

Minnix Lanesha · CIK 0001708662 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,492

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 16:47 UTC
Roque VitorInterim CFO
GrantCommon Stock 931 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-014440 · wk-form4_1772642848.xml · nonDerivative · entry 1

Roque Vitor · CIK 0002098881 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,510

F1 · balance_after: Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 16:45 UTC
Spikner Pamela L.SVP Controller & CAO
GrantCommon Stock 931 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-014438 · wk-form4_1772642743.xml · nonDerivative · entry 1

Spikner Pamela L. · CIK 0002012329 · SVP Controller & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,323

F1 · balance_after: Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Read SEC document
February 26, 2026 Filed Feb 27, 2026 22:45 UTC
Feld MichaelEVP, Chief Revenue Officer
SaleCommon Stock 75 $181.84 $13,638.00
Disclosure

SEC source: 0001628280-26-012955 · wk-form4_1772232327.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,308

F1 · balance_after: Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Read SEC document
February 18, 2026 Filed Feb 18, 2026 22:20 UTC SaleCommon Stock 953 $182.61 $174,027.33
Disclosure

SEC source: 0001628280-26-009242 · wk-form4_1771453248.xml · nonDerivative · entry 1

SCOTT BERTRAM L · CIK 0001221780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,763

Read SEC document
February 04, 2026 Filed Feb 5, 2026 17:24 UTC GrantRights to Common Stock Under BD Deferred Compensation Plan · Derivative 100 $201.91 $20,191.00
Disclosure

SEC source: 0001628280-26-005700 · wk-form4_1770312252.xml · derivative · entry 1

Huffines Robert Luther · CIK 0001728221 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100

Underlying: Common Stock · 100 shares

Expires not disclosed

F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

Read SEC document
February 04, 2026 Filed Feb 5, 2026 17:21 UTC GrantRights to Common Stock Under BD Deferred Compensation Plan · Derivative 30 $201.91 $6,057.30
Disclosure

SEC source: 0001628280-26-005695 · wk-form4_1770312101.xml · derivative · entry 1

Byington Carrie L · CIK 0001890265 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,714

Underlying: Common Stock · 30 shares

Expires not disclosed

F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F3 · balance_after: Includes rights acquired through dividend reinvestment since the last report filed by the reporting person.

Read SEC document
February 04, 2026 Filed Feb 5, 2026 17:18 UTC GrantRights to Common Stock Under BD Deferred Compensation Plan · Derivative 272 $201.91 $54,919.52
Disclosure

SEC source: 0001628280-26-005690 · wk-form4_1770311892.xml · derivative · entry 1

Jones Christopher Ian Montague · CIK 0001292762 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,649

Underlying: Common Stock · 272 shares

Expires not disclosed

F1 · derivative.exercise_price: The securities convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F2 · derivative.expiration_date: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.

F3 · balance_after: Includes rights acquired through dividend reinvestment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:57 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004017 · wk-form4_1769698638.xml · nonDerivative · entry 1

ECKERT R ANDREW · CIK 0001210525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,423

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:58 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004019 · wk-form4_1769698710.xml · nonDerivative · entry 1

Henderson Jeffrey William · CIK 0001324015 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,143

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:56 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004015 · wk-form4_1769698563.xml · nonDerivative · entry 1

Byington Carrie L · CIK 0001890265 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,018

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:52 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004010 · wk-form4_1769698358.xml · nonDerivative · entry 1

Brown William M · CIK 0001350633 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,663

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:54 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004013 · wk-form4_1769698476.xml · nonDerivative · entry 1

HAYES GREGORY · CIK 0001225946 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,159

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:50 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004008 · wk-form4_1769698237.xml · nonDerivative · entry 1

Huffines Robert Luther · CIK 0001728221 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,279

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:48 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004006 · wk-form4_1769698133.xml · nonDerivative · entry 1

Jones Christopher Ian Montague · CIK 0001292762 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,304

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:47 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004004 · wk-form4_1769698020.xml · nonDerivative · entry 1

RING TIMOTHY M · CIK 0001204666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,160

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:45 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-004002 · wk-form4_1769697927.xml · nonDerivative · entry 1

SCOTT BERTRAM L · CIK 0001221780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,716

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:44 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003999 · wk-form4_1769697838.xml · nonDerivative · entry 1

Waldstreicher Joanne · CIK 0001962413 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,391

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 14:42 UTC GrantCommon Stock 1,098 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003997 · wk-form4_1769697739.xml · nonDerivative · entry 1

Wright Jacqueline · CIK 0001806405 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,279

F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person.

Read SEC document
January 26, 2026 Filed Jan 28, 2026 14:46 UTC
Feld MichaelEVP, CRO & Pres. Life Sciences
SaleCommon Stock 75 $202.73 $15,204.75
Disclosure

SEC source: 0001628280-26-003734 · wk-form4_1769611611.xml · nonDerivative · entry 1

Feld Michael · CIK 0002034349 · EVP, CRO & Pres. Life Sciences

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,431

Read SEC document
January 21, 2026 Filed Jan 23, 2026 14:46 UTC
Spikner Pamela L.SVP Controller & CAO
Tax withholdingCommon Stock 84 $0.00 $0.00
Disclosure

SEC source: 0002012329-26-000002 · wk-form4_1769179611.xml · nonDerivative · entry 1

Spikner Pamela L. · CIK 0002012329 · SVP Controller & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,832

F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units previously reported on Table I.

Read SEC document
January 15, 2026 Filed Jan 16, 2026 20:43 UTC
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
Exercise / conversionStock Appreciation Rights · Derivative 3,054 $0.00 Strike: $167.91 $0.00
Disclosure

SEC source: 0001944816-26-000002 · wk-form4_1768596224.xml · derivative · entry 5

Garrison Michael David · CIK 0001944816 · EVP & Pres Med.Essntl&BioPharm

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,054 shares

Expires 2026-11-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock appreciation rights vested in four annual installments beginning one year from the grant date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.